Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer
| Autor: | Yasuharu Kaizaki, Takao Iida, Yukie Mizuno |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Proto-Oncogene Proteins B-raf Time Factors Colorectal cancer Clinical Biochemistry DNA Mutational Analysis Biology medicine.disease_cause Real-Time Polymerase Chain Reaction Biochemistry 03 medical and health sciences Exon 0302 clinical medicine Growth factor receptor medicine Humans Bridged nucleic acid Biochemistry (medical) General Medicine DNA medicine.disease Molecular biology digestive system diseases genomic DNA 030104 developmental biology Real-time polymerase chain reaction 030220 oncology & carcinogenesis Nucleic acid ras Proteins KRAS Colorectal Neoplasms |
| Zdroj: | Clinica chimica acta; international journal of clinical chemistry. 489 |
| ISSN: | 1873-3492 |
| Popis: | Mutations in RAS and BRAF are predictors of the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). Therefore, simple, rapid, cost-effective methods to detect these mutations in the clinical setting are greatly needed. In the present study, we evaluated BNA Real-time PCR Mutation Detection Kit Extended RAS (BNA Real-time PCR), a real-time PCR method that uses bridged nucleic acid clamping technology to rapidly detect mutations in RAS exons 2-4 and BRAF exon 15. Genomic DNA was extracted from 54 formalin-fixed paraffin-embedded (FFPE) tissue samples obtained from mCRC patients. Among the 54 FFPE samples, BNA Real-time PCR detected 21 RAS mutations (38.9%) and 5 BRAF mutations (9.3%), and the reference assay (KRAS Mutation Detection Kit and MEBGEN™ RASKET KIT) detected 22 RAS mutations (40.7%). The concordance rate of detected RAS mutations between the BNA Real-time PCR assay and the reference assays was 98.2% (53/54). The BNA Real-time PCR assay proved to be a more simple, rapid, and cost-effective method for detecting KRAS and RAS mutations compared with existing assays. These findings suggest that BNA Real-time PCR is a valuable tool for predicting the efficacy of early anti-EGFR therapy in mCRC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect